{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:24:02Z","timestamp":1782307442281,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02935-x","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T17:18:52Z","timestamp":1764004732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice"],"prefix":"10.1186","volume":"24","author":[{"given":"M.","family":"Monmirel-Fauconnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pieronne-Deperrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bonnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Frimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Linghui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ni Dheasmhunaigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Morchid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Renet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dumesnil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"F\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Boulkroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ouvrard-Pascaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2935_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","volume":"315","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315:36\u201346. https:\/\/doi.org\/10.1001\/jama.2015.17346.","journal-title":"JAMA"},{"key":"2935_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCULATIONAHA.106.679779","volume":"116","author":"S Kenchaiah","year":"2007","unstructured":"Kenchaiah S, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2007;116:627\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.679779.","journal-title":"Circulation"},{"key":"2935_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002468","volume":"5","author":"E Zamora","year":"2016","unstructured":"Zamora E, et al. Weight loss in obese patients with heart failure. J Am Heart Assoc. 2016;5:e002468. https:\/\/doi.org\/10.1161\/JAHA.115.002468.","journal-title":"J Am Heart Assoc"},{"key":"2935_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.amjcard.2015.02.024","volume":"115","author":"A Sharma","year":"2015","unstructured":"Sharma A, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115:1428\u201334. https:\/\/doi.org\/10.1016\/j.amjcard.2015.02.024.","journal-title":"Am J Cardiol"},{"key":"2935_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13072086","author":"AJ Hobbach","year":"2024","unstructured":"Hobbach AJ, et al. BMI-stratified exploration of the \u201cobesity paradox\u201d: heart failure perspectives from a large German insurance database. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13072086.","journal-title":"J Clin Med"},{"key":"2935_CR6","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1016\/j.jacc.2017.09.1111","volume":"70","author":"T Tsujimoto","year":"2017","unstructured":"Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70:2739\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1111.","journal-title":"J Am Coll Cardiol"},{"key":"2935_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3270","author":"KH Peck","year":"2024","unstructured":"Peck KH, et al. Intentional weight loss in overweight and obese patients with heart failure: a systematic review. Eur J Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ejhf.3270.","journal-title":"Eur J Heart Fail"},{"key":"2935_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11892-020-01367-z","volume":"20","author":"T Tabucanon","year":"2020","unstructured":"Tabucanon T, et al. Does weight loss improve clinical outcomes in overweight and obese patients with heart failure? Curr Diab Rep. 2020;20:75. https:\/\/doi.org\/10.1007\/s11892-020-01367-z.","journal-title":"Curr Diab Rep"},{"key":"2935_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/oby.22038","volume":"26","author":"D Mikhalkova","year":"2018","unstructured":"Mikhalkova D, et al. Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity (Silver Spring). 2018;26:284\u201390. https:\/\/doi.org\/10.1002\/oby.22038.","journal-title":"Obesity (Silver Spring)"},{"key":"2935_CR10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jacc.2022.08.738","volume":"80","author":"H Sorimachi","year":"2022","unstructured":"Sorimachi H, et al. Long-term changes in cardiac structure and function following bariatric surgery. J Am Coll Cardiol. 2022;80:1501\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.738.","journal-title":"J Am Coll Cardiol"},{"key":"2935_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cardfail.2017.05.005","volume":"23","author":"CE Persson","year":"2017","unstructured":"Persson CE, et al. Risk of heart failure in obese patients with and without bariatric surgery in Sweden-a registry-based study. J Card Fail. 2017;23:530\u20137. https:\/\/doi.org\/10.1016\/j.cardfail.2017.05.005.","journal-title":"J Card Fail"},{"key":"2935_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022930","volume":"10","author":"EC El Hajj","year":"2021","unstructured":"El Hajj EC, et al. Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10:e022930. https:\/\/doi.org\/10.1161\/JAHA.121.022930.","journal-title":"J Am Heart Assoc"},{"key":"2935_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010161","volume":"16","author":"PH Brubaker","year":"2023","unstructured":"Brubaker PH, et al. A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction. Circ Heart Fail. 2023;16:e010161. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.010161.","journal-title":"Circ Heart Fail"},{"key":"2935_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"key":"2935_CR15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390:1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917.","journal-title":"N Engl J Med"},{"key":"2935_CR16","doi-asserted-by":"publisher","DOI":"10.7326\/J23-0101","volume":"176","author":"HJ Ali","year":"2023","unstructured":"Ali HJ, Deswal A. In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk. Ann Intern Med. 2023;176:JC136. https:\/\/doi.org\/10.7326\/J23-0101.","journal-title":"Ann Intern Med"},{"key":"2935_CR17","doi-asserted-by":"publisher","DOI":"10.7326\/ACPJ202011170-051","volume":"173","author":"NL Palaskas","year":"2020","unstructured":"Palaskas NL, Deswal A. In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. Ann Intern Med. 2020;173:JC51. https:\/\/doi.org\/10.7326\/ACPJ202011170-051.","journal-title":"Ann Intern Med"},{"key":"2935_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","author":"M Packer","year":"2024","unstructured":"Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"2935_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026807.","journal-title":"Circulation"},{"key":"2935_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jamacardio.2018.2090","volume":"3","author":"M Packer","year":"2018","unstructured":"Packer M. Obesity-associated heart failure as a theoretical target for treatment with mineralocorticoid receptor antagonists. JAMA Cardiol. 2018;3:883\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2018.2090.","journal-title":"JAMA Cardiol"},{"key":"2935_CR21","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"AC Huby","year":"2015","unstructured":"Huby AC, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015;132:2134\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018226.","journal-title":"Circulation"},{"key":"2935_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013255.","journal-title":"Circulation"},{"key":"2935_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145:437\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057983.","journal-title":"Circulation"},{"key":"2935_CR24","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/dom.13393","volume":"20","author":"M Lachaux","year":"2018","unstructured":"Lachaux M, et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes Metab. 2018;20:2399\u2013407. https:\/\/doi.org\/10.1111\/dom.13393.","journal-title":"Diabetes Obes Metab"},{"key":"2935_CR25","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/ehf2.13219","volume":"8","author":"M Pieronne-Deperrois","year":"2021","unstructured":"Pieronne-Deperrois M, et al. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC heart failure. 2021;8:1933\u201343. https:\/\/doi.org\/10.1002\/ehf2.13219.","journal-title":"ESC heart failure"},{"key":"2935_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/mrm.10676","volume":"51","author":"F Kober","year":"2004","unstructured":"Kober F, et al. High-resolution myocardial perfusion mapping in small animals in vivo by spin-labeling gradient-echo imaging. Magn Reson Med. 2004;51:62\u20137. https:\/\/doi.org\/10.1002\/mrm.10676.","journal-title":"Magn Reson Med"},{"key":"2935_CR27","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1096\/fj.15-274266","volume":"29","author":"F Le Billan","year":"2015","unstructured":"Le Billan F, et al. Cistrome of the aldosterone-activated mineralocorticoid receptor in human renal cells. FASEB J. 2015;29:3977\u201389. https:\/\/doi.org\/10.1096\/fj.15-274266.","journal-title":"FASEB J"},{"key":"2935_CR28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/s0006-2952(00)00305-1","volume":"60","author":"BP Kennedy","year":"2000","unstructured":"Kennedy BP, Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. Biochem Pharmacol. 2000;60:877\u201383. https:\/\/doi.org\/10.1016\/s0006-2952(00)00305-1.","journal-title":"Biochem Pharmacol"},{"key":"2935_CR29","doi-asserted-by":"publisher","first-page":"H1020","DOI":"10.1152\/ajpheart.00465.2014","volume":"308","author":"C Roche","year":"2015","unstructured":"Roche C, et al. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice. Am J Physiol Heart Circ Physiol. 2015;308:H1020-1029. https:\/\/doi.org\/10.1152\/ajpheart.00465.2014.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2935_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1524-6175.2004.03254.x","volume":"6","author":"DS Marks","year":"2004","unstructured":"Marks DS, et al. Mortality in patients with microvascular disease. J Clin Hypertens Greenwich Conn. 2004;6:304\u20139. https:\/\/doi.org\/10.1111\/j.1524-6175.2004.03254.x.","journal-title":"J Clin Hypertens Greenwich Conn"},{"key":"2935_CR31","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1210\/jc.2007-0393","volume":"92","author":"HV Joffe","year":"2007","unstructured":"Joffe HV, et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab. 2007;92:2552\u20138. https:\/\/doi.org\/10.1210\/jc.2007-0393.","journal-title":"J Clin Endocrinol Metab"},{"key":"2935_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2337\/db14-0670","volume":"64","author":"R Garg","year":"2015","unstructured":"Garg R, et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes. 2015;64:236\u201342. https:\/\/doi.org\/10.2337\/db14-0670.","journal-title":"Diabetes"},{"key":"2935_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","volume":"67","author":"A Gueret","year":"2016","unstructured":"Gueret A, et al. Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension. 2016;67:717\u201323. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.06709.","journal-title":"Hypertension"},{"key":"2935_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12968-016-0273-y","volume":"18","author":"NK Naresh","year":"2016","unstructured":"Naresh NK, et al. Cardiovascular magnetic resonance detects the progression of impaired myocardial perfusion reserve and increased left-ventricular mass in mice fed a high-fat diet. J Cardiovasc Magn Reson. 2016;18:53. https:\/\/doi.org\/10.1186\/s12968-016-0273-y.","journal-title":"J Cardiovasc Magn Reson"},{"key":"2935_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbadis.2014.07.004","volume":"1852","author":"MR Kandadi","year":"2015","unstructured":"Kandadi MR, et al. Deletion of protein tyrosine phosphatase 1B rescues against myocardial anomalies in high fat diet-induced obesity: role of AMPK-dependent autophagy. Biochim Biophys Acta. 2015;1852:299\u2013309. https:\/\/doi.org\/10.1016\/j.bbadis.2014.07.004.","journal-title":"Biochim Biophys Acta"},{"key":"2935_CR36","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00125-006-0230-7","volume":"49","author":"F Dong","year":"2006","unstructured":"Dong F, et al. Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia. 2006;49:1421\u201333. https:\/\/doi.org\/10.1007\/s00125-006-0230-7.","journal-title":"Diabetologia"},{"key":"2935_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-015-0312-2","volume":"14","author":"J van Haare","year":"2015","unstructured":"van Haare J, et al. Early impairment of coronary microvascular perfusion capacity in rats on a high fat diet. Cardiovasc Diabetol. 2015;14:150. https:\/\/doi.org\/10.1186\/s12933-015-0312-2.","journal-title":"Cardiovasc Diabetol"},{"key":"2935_CR38","doi-asserted-by":"publisher","first-page":"H1279","DOI":"10.1152\/ajpheart.00049.2017","volume":"314","author":"M Besnier","year":"2018","unstructured":"Besnier M, et al. Protein tyrosine phosphatase 1B inactivation limits aging-associated heart failure in mice. Am J Physiol Heart Circ Physiol. 2018;314:H1279\u201388. https:\/\/doi.org\/10.1152\/ajpheart.00049.2017.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2935_CR39","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1096\/fj.13-245753","volume":"28","author":"M Besnier","year":"2014","unstructured":"Besnier M, et al. Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice. FASEB J. 2014;28:3351\u201361. https:\/\/doi.org\/10.1096\/fj.13-245753.","journal-title":"FASEB J"},{"key":"2935_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yjmcc.2016.09.002","volume":"101","author":"PA Thiebaut","year":"2016","unstructured":"Thiebaut PA, et al. Role of protein tyrosine phosphatase 1B in cardiovascular diseases. J Mol Cell Cardiol. 2016;101:50\u20137. https:\/\/doi.org\/10.1016\/j.yjmcc.2016.09.002.","journal-title":"J Mol Cell Cardiol"},{"key":"2935_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.atherosclerosis.2013.12.032","volume":"233","author":"S Nemoto","year":"2014","unstructured":"Nemoto S, et al. Relationships among protein tyrosine phosphatase 1B, angiotensin II, and insulin-mediated aortic responses in type 2 diabetic Goto-Kakizaki rats. Atherosclerosis. 2014;233:64\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.12.032.","journal-title":"Atherosclerosis"},{"key":"2935_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11010-018-3276-1","volume":"446","author":"UB Mahajan","year":"2018","unstructured":"Mahajan UB, et al. Eplerenone pretreatment protects the myocardium against ischaemia\/reperfusion injury through the phosphatidylinositol 3-kinase\/Akt-dependent pathway in diabetic rats. Mol Cell Biochem. 2018;446:91\u2013103. https:\/\/doi.org\/10.1007\/s11010-018-3276-1.","journal-title":"Mol Cell Biochem"},{"key":"2935_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1161\/01.hyp.26.1.101","volume":"26","author":"A Nicoletti","year":"1995","unstructured":"Nicoletti A, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension. 1995;26:101\u201311. https:\/\/doi.org\/10.1161\/01.hyp.26.1.101.","journal-title":"Hypertension"},{"key":"2935_CR44","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"2935_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, et al. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563\u201375. https:\/\/doi.org\/10.1006\/jmcc.1993.1066.","journal-title":"J Mol Cell Cardiol"},{"key":"2935_CR46","doi-asserted-by":"publisher","first-page":"C570","DOI":"10.1152\/ajpcell.00201.2022","volume":"323","author":"Z Chen","year":"2022","unstructured":"Chen Z, Natarajan R. Epigenetic modifications in metabolic memory: what are the memories, and can we erase them? Am J Physiol Cell Physiol. 2022;323:C570\u201382. https:\/\/doi.org\/10.1152\/ajpcell.00201.2022.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2935_CR47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1186\/s12933-026-03162-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000}}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02935-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02935-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02935-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:38:15Z","timestamp":1778675895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-02935-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2935"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02935-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised Author Names, Tables and Figures have been corrected","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12933-026-03162-8","URL":"https:\/\/doi.org\/10.1186\/s12933-026-03162-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}